Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, et al.
Dermatology and Therapy (2022) Vol. 13, Iss. 1, pp. 221-234
Open Access | Times Cited: 19

Showing 19 citing articles:

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Jenne P. Ingrassia, Muhammad Haisum Maqsood, Joel M. Gelfand, et al.
JAMA Dermatology (2023) Vol. 160, Iss. 1, pp. 28-28
Closed Access | Times Cited: 30
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 27
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 14
Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors
Patrick A. Ireland, Nicholas Jansson, Sascha Spencer, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 3, pp. 281-281
Closed Access | Times Cited: 10
Janus Kinase Inhibitors and Adverse Events of Acne
Jeremy Martinez, Cyriac Manjaly, Priya Manjaly, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 12, pp. 1339-1339
Closed Access | Times Cited: 17
Infection risk with JAK inhibitors in dermatoses: a meta‐analysis
Patrick A. Ireland, Matthew J Verheyden, Nicholas Jansson, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 7
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 10, pp. 1301-1312
Closed Access | Times Cited: 13
Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis
Norio Kawamoto, Hiroki Murai, Kazutaka Nogami, et al.
Allergology International (2025)
Open Access
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024
Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, et al.
Allergology International (2025)
Open Access
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors.
Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, et al.
PubMed (2025)
Closed Access
Upadacitinib for Moderate to Severe Atopic Dermatitis
F.J. Navarro‐Triviño, Sara Alcantara‐Luna, J.J. Domínguez-Cruz, et al.
Immunotherapy (2023) Vol. 15, Iss. 11, pp. 799-808
Closed Access | Times Cited: 9
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
Norito Katoh, Masanori Ikeda, Yukihiro Ohya, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 213-232
Open Access | Times Cited: 7
Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials
Lingmei Huang, Danjie Zhao, Haixia Lin, et al.
Medicine (2024) Vol. 103, Iss. 38, pp. e39826-e39826
Open Access | Times Cited: 2
Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review
Olivia Lamberg, Karan Pandher, Jonathon P. Troost, et al.
Archives of Dermatological Research (2024) Vol. 317, Iss. 1
Closed Access | Times Cited: 2
English version of clinical practice guidelines for the management of atopic dermatitis 2024
Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 1
ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI
Furkan Çalıcıoğlu, Neşecan Çalıcıoğlu, Atıl Avcı, et al.
Journal of Anatolian Medical Research (2024)
Open Access
Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis
Elsy M. Navarrete-Rodríguez, Désirée Larenas‐Linnemann, Helena Vidaurri‐de la Cruz, et al.
Current Allergy and Asthma Reports (2024) Vol. 24, Iss. 9, pp. 485-496
Closed Access
Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review
Dan-Jie Zhao, Xia Li, Hai-Xia Lin, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0306463-e0306463
Open Access
Herpes Zoster Infection in Atopic Patients Undergoing Upadacitinib: Practical Suggestions on Vaccination and Management
Michela Ortoncelli, Luca Mastorino, Federica Gelato, et al.
Dermatitis (2023) Vol. 35, Iss. 3, pp. 305-307
Closed Access
Page 1

Scroll to top